Royal Fornia Electronic Device Co., Ltd. Signs Technology Licensing Agreement to Integrate Masimo rainbow SET Pulse CO-Oximetry Into New Patient Monitors

Thu, 02/24/2011 - 3:37am

IRVINE, Calif. and GUANGDONG PROVINCE, China, Feb. 24, 2011 /PRNewswire/ -- Masimo (Nasdaq: MASI) and Royal Fornia Electronic Device Co., Ltd. jointly announce a worldwide technology licensing agreement to integrate Masimo rainbow SET® Pulse CO-Oximetry™ technology into Royal Fornia's new generation of multiparameter patient monitors—enabling advanced noninvasive blood constituent measurements that help clinicians to detect and treat life-threatening conditions earlier. Having recently received State Food and Drug Administration (SFDA) approval for Masimo rainbow® SET parameters in China, Royal Fornia establishes itself as one of the first domestic Chinese medical device manufacturers to commercially incorporate Masimo's breakthrough noninvasive blood constituent measurement capabilities.

Masimo rainbow® SET noninvasive and continuous measurements—like total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and Pleth Variability Index (PVI®), in addition to the 'gold-standard' Measure-Through Motion and Low Perfusion performance of Masimo SET® oxyhemoglobin (SpO2), perfusion index (PI), and pulse rate (PR)—provide detailed physiological data that helps clinicians to more rapidly assess patients and detect adverse conditions much earlier.  With rainbow® SET measurements, the ability to noninvasively detect internal bleeding, carbon monoxide poisoning, methemoglobinemia, fluid responsiveness, low perfusion, desaturations, and abnormal pulse rates quickly, easily, and continuously




Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.